Here are the 8-K filings from Guggenheim Strategic Opportunities Fund (GOF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow GOF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOF filings page.
Guggenheim Strategic Opportunities Fund entered into new service agreements with The Bank of New York Mellon on December 15, 2025. The fund signed a Fund Administration and Accounting Agreement under which BNY provides administrative, bookkeeping, accounting and pricing services. BNY’s compensation is based on the fund’s average daily net assets, with fees accrued daily, paid monthly and subject to a minimum annual fee, and the fund also reimburses certain out-of-pocket expenses.
The fund also executed a new Custody Agreement and a Foreign Custody Manager Agreement with BNY, replacing prior custody arrangements dated July 26, 2007. BNY will hold the fund’s securities and cash and act as foreign custody manager, receiving a monthly fee tied in part to average daily net assets plus charges for securities transactions. At the same time, the fund terminated its prior administration and accounting agreement with MUFG Investor Services (US) LLC and the prior BNY custody agreements, with no termination or other fees owed beyond ordinary course payments through the termination dates.
Guggenheim Strategic Opportunities Fund has entered into an amended Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., allowing it to offer and sell common shares with an aggregate initial offering price of up to $1,000,000,000. The sales are to be made from time to time through Cantor Fitzgerald acting as agent under the Fund’s effective shelf registration statement on Form N-2. The offering is supported by a prospectus supplement and base prospectus, both dated November 21, 2025, and the Fund commenced sales under this program on November 24, 2025.